MedTrace Logo

Observational Study to Evaluate Therapeutic Effectiveness and Safety of Monterizine Cap.

NCT04654702 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2671

Last updated 2021-11-26

No results posted yet for this study

Summary

Investigator examines the past prescription patterns and the reasons for the change of prescription to Monterizine capsules for Perennial Allergic Rhinitis patients with Asthma who will be taking Monterizine capsules to treat allergic rhinitis.

After being given Monterizine capsules, Investigator evaluates the therapeutic effectiveness and safety for 3 months (or 6 months).

Conditions

  • Perennial Allergic Rhinitis
  • Asthma

Sponsors & Collaborators

  • Hanmi Pharmaceutical Company Limited

    lead INDUSTRY

Principal Investigators

  • Byoung-Whui Choi · 59 institutions including Chung-Ang University Hospital

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-17
Primary Completion
2020-01-10
Completion
2020-07-20

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04654702 on ClinicalTrials.gov